The FDA has accepted and granted Priority Review to a supplemental Biologics License Application (sBLA) filed by AstraZeneca and Daiichi Sankyo for ENHERTU (fam-trastuzumab deruxtecan-nxki) as a post-neoadjuvant treatment for adult patients with HER2-positive (IHC 3+ or ISH+) early breast cancer who present with residual invasive disease following neoadjuvant HER2-targeted therapy. The PDUFA action date is set for Q3 2026.
This designation follows the Breakthrough Therapy Designation (BTD) already granted in this setting, making ENHERTU the recipient of its tenth BTD, and places it on an accelerated regulatory pathway that could fundamentally alter commercial dynamics across the HER2-positive early breast cancer segment. The sBLA is also under concurrent review via the FDA’s Project Orbis framework, with regulatory submissions pending in the EU and Japan.
Clinical Evidence Driving the ENHERTU Priority Review
The Priority Review is anchored in results from the DESTINY-Breast05 Phase III trial — a global, randomized, open-label study enrolling 1,635 patients — presented in a Presidential Symposium at the ESMO 2025 Congress and subsequently published in The New England Journal of Medicine.
Against T-DM1, the current standard of care in this setting, ENHERTU delivered a 53% reduction in the risk of invasive disease recurrence or death (HR=0.47; 95% CI: 0.34–0.66; p<0.0001). The 3-year invasive disease-free survival rate reached 92.4% with ENHERTU versus 83.7% with T-DM1. The regimen also reduced the risk of distant recurrence by 51% and the risk of brain metastases by 36%.
What does ENHERTU’s approval mean for competing HER2-directed therapies in your pipeline? Download DelveInsight’s HER2-Positive Breast Cancer Competitive Landscape Intelligence.
ENHERTU Priority Review: Commercial and Pipeline Implications
Approximately one in five breast cancer cases are classified as HER2-positive, a subtype historically associated with aggressive disease biology and elevated recurrence risk. In the US, roughly 15,000 patients annually are treated in the post-neoadjuvant setting, a commercially significant population that has lacked superior therapeutic options beyond T-DM1. If approved, ENHERTU would displace T-DM1 as the reference standard, reshaping market share dynamics, treatment sequencing strategies, and payer formulary decisions across this indication.
A parallel sBLA for ENHERTU combined with paclitaxel, trastuzumab, and pertuzumab (THP) in the neoadjuvant setting (based on DESTINY-Breast11 data) is also currently under FDA review with a PDUFA date of May 18, 2026. Together, these submissions position ENHERTU across both ends of the early breast cancer treatment continuum, with compounding implications for competitive pipeline positioning and lifecycle management strategies.
How large is the addressable opportunity and who captures it? Our report quantifies the post-neoadjuvant HER2-positive patient pool across the US, EU4, UK, and Japan, with scenario-based revenue forecasts reflecting ENHERTU’s likely market entry timeline. Request the HER2-Positive Breast Cancer Market Sizing Data
DelveInsight Perspective
For pharma executives tracking the HER2-positive breast cancer landscape, the convergence of a Priority Review, Breakthrough Therapy Designation, and Project Orbis scope represents one of the most commercially consequential regulatory sequences observed in early breast cancer in recent years. The ripple effects on biosimilar trastuzumab uptake, ADC market penetration, competitive pipeline prioritization, and regional market access strategies will demand immediate strategic attention.
DelveInsight’s HER2-Positive Breast Cancer Market Report provides the granular intelligence needed to navigate this rapidly evolving landscape: epidemiology forecasts, therapy uptake modeling, competitive pipeline assessments, and market sizing through 2034.
Speak directly with our oncology analysts. If your team is reassessing commercial strategy, pipeline positioning, or licensing decisions in light of this approval, our analysts are available for a tailored briefing.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services